Peer-reviewed veterinary case report
A noninferiority trial evaluating the efficacy of bedinvetmab compared to grapiprant for osteoarthritis-pain in dogs using force plate gait analysis.
- Journal:
- Scientific reports
- Year:
- 2026
- Authors:
- Enomoto, Masataka et al.
- Affiliation:
- College of Veterinary Medicine · United States
- Species:
- dog
Plain-English summary
In a study involving 32 dogs over one year old and weighing more than 20 kg, researchers compared two medications, bedinvetmab and grapiprant, to see which one was more effective at relieving pain from osteoarthritis (a joint condition) in the hips and/or knees. The dogs were randomly assigned to receive either bedinvetmab once a month with a placebo daily or grapiprant daily with a saline injection monthly. After two months, the results showed that 68.8% of the dogs on bedinvetmab had improvement in their pain levels, compared to 56.3% for those on grapiprant. Since the difference in effectiveness was within an acceptable range, bedinvetmab was found to be just as effective as grapiprant. Both treatments were shown to significantly improve pain and related symptoms, making them both good options for managing osteoarthritis pain in dogs.
Abstract
A randomized, double-blind, non-inferiority study was conducted to evaluate efficacy of bedinvetmab compared to grapiprant using objective force plate gait analysis (FPGA). Thirty-two eligible dogs (> 20 kg, ≥ 1 year-old) with osteoarthritis (OA) exclusively at hips and/or stifles were randomized 1:1 to the licensed dose of monthly subcutaneous (SC) bedinvetmab (plus daily oral placebo) or daily oral grapiprant (plus monthly SC saline) beginning on day 0 (D0). FPGA and client-reported outcome measures (CROMs) were collected at screening, D0, and every 14 days for 2 months. Based on published FPGA parameters, success-failure rates were calculated for each group. A non-inferiority margin of 21.25% at D42 was defined a priori. FPGA treatment success rate at D42 was 68.8% for bedinvetmab and 56.3% for grapiprant, with the difference being 12.5% (90% confidence interval = -37.5, 18.8). Given that the upper bound of this interval (18.8%) was less than the pre-specified non-inferiority margin of 21.25%, bedinvetmab was concluded to be non-inferior to grapiprant. Overall, pain and associated clinical signs were significantly improved after both treatments based on CROMs. Adverse events were in line with respective label expectations. These data support both bedinvetmab and grapiprant are appropriate first-line treatments for OA pain in dogs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication: https://pubmed.ncbi.nlm.nih.gov/41667566/